Great BP exposure will add further credibility to Immutep's oral...

Great BP exposure will add further credibility to Immutep's oral TACTI-002 presentation :-

BMS presenting more mature data for anti Lag-3 Opdualag at ASCO 22

Opdualag earned its FDA approval in melanoma based on Relativity-047 data showing it could pare down the risk of disease progression or death by 25% over Opdivo alone.

Because Opdualag adds anti-LAG-3 antibody relatlimab to Opdivo, people might suspect that Opdualag’s benefit was only for those patients whose tumors expressed LAG-3. But that doesn’t seem to be the case in Relativity-047.
In patients who had tumor LAG-3 expression at or above 1%, Opdualag cut the risk of disease progression or death by 20% over Opdivo.
And the reduction was 28% in those with LAG-3 expression below 1%.

Mark Rutstein, M.D., vice president of Opdivo development at BMS said, “some variability” in Opdualag’s showing in a couple subgroups, where the evidence of benefit appeared stronger for some patients. For example, in PD-L1 expressors, for whom PD-1 inhibitors like Opdivo typically work better than in PD-L1 non-expressors, patients had roughly the same risk of disease progression or death between Opdualag and Opdivo.

But in patients with PD-L1 less than 1%, Opdualag offered a 32% risk reduction in progression-free survival.